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Core tip: The common presence of two thrombophilic
defects increases the thrombotic risk several folds above
the risk of a single defect and these tend to occur at an
earlier age as seen in our case. Also the risk of recurrent thrombosis is significantly increased among these
heterozygotes. Indefinite anticoagulation with oral anticoagulants (goal International Normalized Ratio = 2-3)
is recommended for high risk patients like our case with
thrombosis at unusual sites (e.g. , mesenteric vein), and
heterozygosity for both factor V Leiden and prothrombin G20210A mutations. These patients should avoid
any hormonal therapy and family members should be
screened for underlying prothrombotic condition.

Abstract
Mesenteric venous thrombosis (MVT) is a rare but life
threatening form of bowel ischemia. It is implicated
in 6%-9% of all cases of acute mesenteric ischemia.
The proportion of patients with primary (or idiopathic)
MVT varies from 0% to 49%, with a decrease in frequency secondary to more recent availability of newer
investigations for hypercoagulability. The presence of
factor V Leiden (FVL) and prothrombin G20210A mutations (PGM) have been well documented in these
cases. However, there have been scarce case reports
describing MVT in heterozygotes of both these mutations occurring simultaneously and its implications on
long term management. Our case describes acute MVT
in a previously asymptomatic young patient with no
prior history of venous thromboembolism. The patient
was found to be heterozygous for FVL and PGM and
treated with lifelong anticoagulation with warfarin (goal
international normalized ratio: 2-3) and avoidance of
hormonal contraceptives.
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INTRODUCTION
Mesenteric venous thrombosis (MVT) is a rare but life
threatening form of bowel ischemia, responsible for 6%-9%
of all acute mesenteric ischemia. The presence of factor V
Leiden (FVL) and prothrombin G20210A mutations (PGM)
have been well documented in these cases. However, there
have been scarce case reports describing MVT in heterozygotes of both these mutations occurring simultaneously
and its implications on long term management.

© 2013 Baishideng Publishing Group Co., Limited. All rights
reserved.

CASE REPORT
A 22-year-old Caucasian female presented to the emer-
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gency department with progressively worsening, colicky
left upper quadrant abdominal pain for 4 d with radiation
to her back, associated with some nausea. She denied any
history of fever or changes in bowel movements. Past
medical history was significant for Polycystic Ovarian
syndrome treated with oral contraceptives. She denied
personal or family history of thrombosis. Physical exam
was significant for tenderness on left upper quadrant of
abdomen without guarding, rigidity or rebound tenderness. Complete blood count and electrolytes were within
normal limits. A computed tomography (CT) scan of
the abdomen revealed possible superior mesenteric vein
(SMV) thrombosis without evidence of bowel ischemia
(Figure 1). Patient was started on enoxaparin (1 mg/kg
twice daily) with bridging to warfarin. Subsequent CT
angiography confirmed the initial diagnosis of SMV
thrombosis. Surgical intervention was not indicated due
to lack of bowel ischemia. Workup for possible vasculitis, including antinuclear antibody, Anti-neutrophil
cytoplasmic antibody, titers of hepatitis B, hepatitis C,
and Human Immunodeficiency Virus screening were all
negative. Hypercoagulable evaluation including protein-C
and S, antithrombin Ⅲ, anticardiolipin antibodies were all
negative. However she was found to have heterozygous
mutations for both prothrombin G20210A and FVL. She
was discharged on warfarin with a therapeutic level of anticoagulation. She was advised to have lifelong anticoagulation with warfarin [goal International Normalized Ratio
(INR) = 2-3] and avoidance of hormonal contraceptives.

Figure 1 Contrast-enhanced computed tomography scan. It shows decreased attenuation within the superior mesenteric vein (arrow), immediately
below the portal confluence, compatible with venous thrombosis.

the initial presentation in a patient with combined heterozygosity for FVL mutation and the G20210A prothrombin gene variation in the face of oral contraceptive use.
The association of each of these mutations with thrombotic disease has been well established. Among Caucasian
patients presenting with an initial episode of idiopathic
deep venous thrombosis, 12%-20% will be found to be
heterozygous for the FVL mutation and 6% heterozygous for the prothrombin G20210A gene variation as
compared to 6% and 2% respectively, in asymptomatic
Caucasian controls[7]. A recent retrospective study by
Amitrano et al[5] noted a high prevalence of thrombophilic
genotypes (75%): FVL (25%), prothrombin G20210A
gene (25%), and MTHFR prothrombotic defects (50%)
in patients with acute mesenteric vein thrombosis. Double heterozygotes of FVL mutation and the prothrombin
G20210A gene variation have been shown to be associated with a greater risk of venous thrombosis than either
defect alone. Also the age at the first episode of venous
thromboembolism in double heterozygotes was significantly younger than those without both gene defects (34.7
years vs 40.6 years; P < 0.01) in observational and metaanalytic studies. Finally, use of OCP’s was associated with
a significantly increased risk of thrombosis over those
not using them (OR = 16.97, 95%CI: 3.95-72.80)[8-11].
It seems plausible that in our case, MVT was induced
by OCPs on the background of her hematological disorders leading to a hypercoagulable state. The common
presence of two thrombophilic defects increases the
thrombotic risk several folds above the risk of a single
defect and these tend to occur at an earlier age which
was also seen in our case[10]. Also the risk of recurrent
thrombosis is significantly increased among these heterozygotes. Indefinite anticoagulation with oral anticoagulants (with goal INR = 2-3) is recommended for high risk
patients like our case with thrombosis at unusual sites (e.g.,
mesenteric vein), and heterozygosity for both FVL and
PGM[9,12,13]. These patients should avoid any hormonal
therapy including OCPs due to increased risk of blood
clots. It may also be advised to screen the family members for underlying prothrombotic condition, even with a

DISCUSSION
MVT is a rare but potentially life threatening cause of
mesenteric ischemia with high recurrence rates[1,2]. It is
implicated in 6%-9% of all cases of acute mesenteric
ischemia[1,3,4]. Predisposing conditions including myeloproliferative disorders, neoplasia, hereditary hemorrhagic
telangiectasia, paroxysmal nocturnal hemoglobinuria,
inherited thrombophilias, oral contraceptive pill (OCP)
use, pancreatitis, recent abdominal surgery or local intraabdominal infections can be identified in most patients[5]. When no underlying etiology is identified, MVT
is described as primary or idiopathic. The proportion of
patients with primary (or idiopathic) MVT varies from 0%
to 49%, with a decrease in frequency secondary to more
recent availability of newer investigations for hypercoagulability. Abdominal pain is the most common symptom,
especially with acute thrombosis, whereas chronic MVT
usually manifests as portal hypertension or diagnosed
incidentally by imaging. The increasing use of CT for the
investigation of abdominal pain and anticoagulation for
the treatment of acute MVT have improved outcomes
in these patients[6]. Surgery and bowel resection may occasionally be needed for patients with bowel infarction,
perforation, and peritonitis. The management of patients
with chronic MVT is aimed at reducing complications of
portal hypertension[4,6].
The present case is of interest in that acute MVT was
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first episode of idiopathic venous thrombosis[7,11].
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